Skip to main content

Table 2 Meta-regression analysis

From: The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis

  estimate se zval pval ci.lb ci.ub
Region of publication
(Europe vs. America vs. Asia)
−0.5757 2.4462 −0.2354 0.8139 −5.3702 4.2187
Year of publication
(Before 2000 vs. after 2000)
−2.8189 1.4811 −1.9032 0.057 −5.7218 0.084
Tumor size (<  24 vs. ≥24 months) −0.6388 1.0198 −0.6263 0.5311 −2.6376 1.3601
Drug type (bromocriptine vs. cabergoline) −1.9056 1.5734 −1.2111 0.2258 −4.9895 1.1783
Treatment duration
(< 24 vs. ≥24 months)
−1.0916 1.0284 −1.0614 0.2885 −3.1072 0.9241
Follow-up time
(< 12 vs. 12–24 vs. < 24 months)
0.814 1.2451 0.6538 0.5132 −1.6263 3.2544
  1. se: standard error; zval: z value; pval: p value; ci.lb.: Lower bounds of 95% confidential interval; ci.ub: Upper bounds of 95% confidential interval;